thiaton: antispasmodic; RN refers to bromide (trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tiquizium bromide : A organic bromide salt of tiquizium. It is an antispasmodic drug used for the treatment of convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 72159 |
| CHEMBL ID | 2360047 |
| CHEBI ID | 32232 |
| SCHEMBL ID | 24151 |
| MeSH ID | M0097604 |
| Synonym |
|---|
| tiquizium bromide [inn:jan] |
| tiquizii bromidum [inn-latin] |
| trans-3-(di-2-thienylmethylene)octahydro-5-methyl-2h-quinolizinium bromide |
| bromuro de tiquizio [inn-spanish] |
| 3-(di(2-thienyl)methylene)-5-methyldecahydroquinolizinium bromide |
| hsr 902 |
| 3-(di-2-thienylmethylene)-5-methyl-trans-quinolizidinium bromide |
| quinolizinium, decahydro-3-(di(2-thienyl)methylene)-5-methyl-, bromide, (e)- |
| dithienylmethylene methyl trans-quinolizidinium |
| bromure de tiquizium [inn-french] |
| hsr-902 |
| tiquizium bromide |
| thiaton |
| D01875 |
| thiaton (tn) |
| 71731-58-3 |
| tiquizium bromide (jan/inn) |
| NCGC00167984-01 |
| dtxcid0026757 |
| tox21_112604 |
| dtxsid2046757 , |
| cas-71731-58-3 |
| unii-659k6049sf |
| tiquizii bromidum |
| 659k6049sf , |
| bromure de tiquizium |
| bromuro de tiquizio |
| tiquizium bromide [jan] |
| tiquizium bromide [mi] |
| tiquizium bromide [mart.] |
| tiquizium bromide [inn] |
| tiquizium bromide [who-dd] |
| (+/-)-trans-3-(di-2-thienylmethylene)octahydro-5-methyl-2h-quinolizinium bromide |
| AKOS025311222 |
| smr004701242 |
| MLS006010103 |
| SCHEMBL24151 |
| CHEMBL2360047 |
| (5r,9ar)-3-[di(thiophen-2-yl)methylidene]-5-methyloctahydro-2h-quinolizin-5-ium bromide |
| aspora |
| CHEBI:32232 |
| advaston |
| thiameron |
| (5r,9ar)-3-[di(thiophen-2-yl)methylidene]-5-methyloctahydro-2h-quinolizinium bromide |
| tiapaston |
| thiwan |
| breiful |
| gastirol |
| (5r)-3-(dithiophen-2-ylmethylene)-5-methyldecahydroquinolizinium bromide |
| (5r,9ar)-7-(dithiophen-2-ylmethylidene)-5-methyl-1,2,3,4,6,8,9,9a-octahydroquinolizin-5-ium;bromide |
| 2h-quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-,bromide, (5r,9ar)-rel- |
| Q27263861 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The relative bioavailability was 26%." | ( Absorption, excretion and metabolism of tiquizium bromide in dogs, and relationship between pharmacological effect and plasma levels of unchanged drug. Kato, H; Nagata, O; Nishikawa, T; Takahara, Y; Tanbo, K; Yamada, T; Yamamoto, Y, 1985) | 0.54 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " HSR-902, as well as tolazoline hydrochloride, an alpha-blocking agent, shifted the dose-response curve of noradrenaline-contraction in parallel to the right without decreasing maximal response in the isolated aorta of guinea pig, and the plots of Schild were found to be linear." | ( [Pharmacological studies on antispasmodics. IV. Ganglion blocking activity of 3-(di-2-thienylmethylene)-5-methyl-trans-quinolizidinium bromide (HSR-902) and the correlation between its blocking activity and its inhibitory activity towards urinary bladder Kato, H; Kubo, S; Matsubara, I; Morikawa, K; Yamazaki, M, 1981) | 0.26 |
| Role | Description |
|---|---|
| muscarinic antagonist | A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. |
| antispasmodic drug | A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder. |
| anti-ulcer drug | One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organic bromide salt | |
| quaternary ammonium salt | Derivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 22.7231 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 19.5848 | 0.0002 | 21.2231 | 8,912.5098 | AID743042; AID743054 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 22.0869 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 2.2387 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.0750 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 14.1254 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (61.11) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.17) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.56%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (5.56%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||